

## PERSONAL INFORMATION

Stefania Nobili

✉ stefania.nobili@unich.it

🌐 ORCID: 0000-0003-4731-9169

Sex F | Date of birth 22/10/1965 | Nationality Italian

## CURRENT POSITION

2020: Assistant Professor in Pharmacology (RTD B - BIO/14)  
Department of Neurosciences, Imaging and Clinical Sciences  
University of Chieti-Pescara “G. d’Annunzio” (Chieti, Italy) (UdA)

## EDUCATION

- 2002: Ph.D. in Chemotherapy, University of Milan, Milan, Italy
- 1997: Specialty School Degree in Applied Pharmacology, University of Florence (UniFI), Florence, Italy
- 1989: Pharm. D. School of Pharmacy, University of Rome “La Sapienza”, Rome, Italy
- 1984: Classical High School Degree, Marco Terenzio Varrone, Rieti, Italy

## PREVIOUS POSITIONS

- 2020-2020: Technician, Cat D, Department of Health Sciences, UniFI
- 2019-2020: Research Fellow, Department of Health Sciences, UniFI
- 2014-2019: Assistant Professor in Pharmacology (RTD A – BIO/14), Department of Health Sciences, UniFI
- 2007-2013: Assistant Professor in Pharmacology (RTD – BIO/14), Department of Pharmacology, UniFI
- 2005-2007: Research Associate, Department of Pharmacology, UniFI
- 2002-2005: Postdoctoral Fellow (Assegnista di Ricerca), Department of Pharmacology, UniFI

## AWARDS AND HONORS

*Academic achievements:*

- 2018: National Scientific Qualification (ASN) as Associate Professor (AP) in Medical Oncology (MED/06) (Call 2016)
- 2018: National Scientific Qualification (ASN) as AP in Pharmacology (BIO/14) (Call 2016)
- 2018: National Scientific Qualification (ASN) as AP in Sciences of Health Professions and Applied Medical Technologies (MED/46) (Call 2016)
- 2014: National Scientific Qualification (ASN) as AP in Pharmacology (BIO/14) (Call 2012)

*Scientific prizes:*

- 2017: “Fondo per il finanziamento delle attività base di ricerca 2017 (FFABR)” (ANVUR- Italian Ministry of University (MIUR) according to bibliometric indicators of scientific publications from 2012 to 2016)
- 2013: “Alberico Benedicenti” Award (Italian Society of Pharmacology, Turin)
- 2009: “Emilio Trabucchi” Award (Italian Society of Chemotherapy, Udine)

*Scientific acknowledgements:*

- **Nobili S.** et al “Overcoming tumor multidrug resistance using drugs able to evade P- glycoprotein or to exploit its expression”. *Medicinal Research Reviews*, 32: 1120-1272, 2012)  
2015: Award for the most cited article (Top-six) in *Medicinal Research Reviews* 2011-2012
- **Nobili S.**, et al. Gold compounds as anticancer agents: chemistry, cellular

pharmacology and preclinical studies. *Medicinal Research Reviews*, 30: 550-580, 2010  
2013: Award for the most cited article in *Medicinal Research Reviews* 2010-2011

- **Nobili S**, et al. Natural compounds for cancer treatment and prevention. *Pharmacological Research* 59: 365-378, 2009  
2012: Award for the most cited article in *Pharmacological Research* 2009-2011

#### TRAINING OR RESEARCH AT QUALIFIED NATIONAL OR INTERNATIONAL INSTITUTIONS

- 2001: Visiting Fellow at the Department of Oncology (Prof. Patrick G. Johnston), Queen's University, Belfast, UK
- 2019: Training course: "NGS data analysis and applications in diagnostics", Department of Sciences of Nervous System and Behaviour, University of Pavia, Pavia, Italy

#### MEMBERSHIP OF ACADEMIC COMMITTEES – UNTIL 2019

- Council of the of the School of Pharmacy, UniFI
- Council of the of the School of Biotechnology, UniFI
- Council of the of the School of Nursing, UniFI
- Council of the Specialty School in Medical Oncology, UniFI
- Council of the Specialty School in Hospital Pharmacy, UniFI
- Council of the Specialty School in Clinical Pharmacology and Toxicology, UniFI
- Inter-Departmental Center 'Research on Pharmacoutilization, Pharmacoeepidemiology, Pharmacovigilance and Pharmacoeconomy' (C.I.R.F.), UniFI

#### MEMBERSHIP OF ACADEMIC COMMITTEES – FROM 2020

- Council of the Specialty School in Allergology and Immunology, UdA
- Council of the Specialty School in Gynecology and Obstetrics, UdA
- Council of the Specialty School in Pediatrics, UdA

#### MEMBERSHIPS OF SCIENTIFIC SOCIETIES/BOARDS

- 2020: Joint Research Unit ONCONEST - delegate for UniFI
- 2019-present: Italian Medicines Agency (AIFA) - expert/consultant
- 2018-present: Pharmacological & Molecular Mechanisms (PAMM) Group of the European Organization for Research and Treatment of Cancer (EORTC) - member
- 2017-present: PathoBiology Group (EORTC) - member
- 2012-present: Working Group on Pharmacology Oncology of the Italian Society of Pharmacology (SIF) - member
- 2003-present: Italian Society of Pharmacology (SIF) - member
- 1996-present: Italian Society of Chemotherapy (SIC) - member

#### EDITORIAL ACTIVITY

##### ***Section Editor position:***

- 2020- All Life - Section Editor for Pharmacology and Pharmaceutics

##### ***Associate Editor positions:***

- 2015- Editor of the E-book 'Multidrug resistance in cancer: molecular basis, pharmacological strategies and clinical issues' for *Frontiers in Pharmacology*
- 2012-2020 Associate Editor of *BMC Pharmacology & Toxicology*

##### ***Editorial Board positions:***

- 2020- *Cancer Cells and Therapy*; 2020- *ABRT* (AME Bond Editors and Reviewers); 2020- *BMC Pharmacology & Toxicology*; 2019- *Oncology Research*; 2016- *Expert in Medicinal Chemistry*; 2015- *Frontiers in Pharmacology*; 2015- *Frontiers in Oncology*; 2012- *American Journal of Pharmacological Sciences*; 2011- *Journal of Chemotherapy*

### Guest Editor:

- Cancer Drug Resistance – Special Issue ‘Cancer Pharmacogenetics’ (2020)
- Journal of Personalized Medicine - Special Issue ‘Gastrointestinal Cancer and Personalized Medicine’ (ongoing)
- Journal of Personalized Medicine - Special Issue ‘Biomarkers in Colorectal Cancer’ (ongoing)

### REVIEWER ACTIVITY

#### Peer reviewed journals

Dr. Nobili regularly reviews papers on cancer pharmacology and medical oncology for several peer reviewed journals, including: Medicinal Research Reviews, International Journal of Cancer, Scientific Reports, Oncotarget, Expert Opinion on Investigational Drugs, Biomolecules; Journal of Personalized Medicine; Pharmacogenomics Journal, Marine Drugs, International Journal of Nanomedicine. She has also reviewed chapters for E-books of Elsevier Science Publishers, OMICS Group International, etc.

#### Scientific Institutions

- 2019: External Peer of the LEaDing Fellows Postdocs Programme - a joint initiative of 5 Universities in the Netherlands - H2020-Marie Skłodowska-Curie COFUND Programme (Third call 2018)
- 2019-2021: Member of the evaluation committee of the H2020 FET OPEN RIA “AMPHORA” project (Call 2017-1 European Commission - (Bruxelles, Belgio)
- From 2016: Remote evaluator for the H2020 FET OPEN RIA (Novel Ideas for Radically New Technologies) - European Commission (Bruxelles, Belgium)

### RESEARCH PROJECTS/ FUNDING

Principal Investigator of projects granted by national and international institutions (e.g. Fondazione Cassa di Risparmio di Firenze [Rif. n. 2013.0842; Rif. n. 2014.0969]; Worldwide Ion Torrent Transcriptome Profiling Grant Program 2015”, ThermoFisher Scientific, San Francisco (CA, USA)

Responsible for research activity in projects granted by Tuscany Region – Research Grant 2018 [KNOWPAIN], Fondazione Cassa di Risparmio di Firenze [Rif. n. 2018.1147; Rif. n. 2020.1521]

Participant in several scientific projects granted by institutional national (Italian University Ministry - MIUR, Rome; Italian Health Ministry, Rome, Italian Association for Cancer Research - AIRC, Milan) and international agencies (e.g. Cancer Research UK; H2020 [e.g. H2020-SC1-2019-Two-Stage-RTD - Project 848098 “REVERT”; EUNIWELL), as well as private foundations.

### CLINICAL TRIAL EXPERIENCE

- Participant in the conception and design of translational pharmacological clinical trials of anticancer chemotherapy.
- Participant in national and international pharmacological clinical trials of anticancer chemotherapy.

### INVITED TALKS

Dr. Nobili has been invited to give talks in national and international meetings

### TEACHING ACTIVITY AT INTERNATIONAL INSTITUTIONS AND UNIVERSITIES

2015: Erasmus Teaching Programme, Faculty of Pharmacy, Granada University (Spain) - Pharmacology course

### TEACHING ACTIVITY AT THE UNIVERSITY OF FLORENCE

Lessons of Pharmacology: *Undergraduate Schools*: Pharmacy, Biotechnologies (I level and II level), Nursing; *Specialty Schools*: Hospital Pharmacy, Medical Oncology; several II and I level *Masters*.

## TEACHING ACTIVITY AT "G. D'ANNUNZIO" UNIVERSITY OF CHIETI-PESCARA

Lessons of Pharmacology: *Specialty Schools (School of Medicine)*: Allergology and Immunology, Gynecology and Obstetrics; Pediatrics.

## THESIS SUPERVISOR/ CO-SUPERVISOR

From 2009: Students of School of Pharmacy, Medicine and Surgery, Biotechnologies and clinicians of the Specialty School in Medical Oncology.

## MAJOR RESEARCH INTERESTS

- Preclinical and clinical pharmacology of anticancer drugs
- Cancer pharmacogenetics and pharmacogenomics
- Molecular mechanisms of tumor drug resistance

## SCIENTIFIC INFORMATION IN INTERNATIONAL REPOSITORIES

**KP090034:** NCBI GenBank (<http://www.ncbi.nlm.nih.gov/nucleotide/KP090034>) - Homo sapiens MHC class I antigen (HLA-G) gene, 3' UTR.

Garziera M, Cecchin E, Lonardi S, Mini E, Nobili S, Romanato L, Toffoli, G. A novel germline mutation +3037 C>A and presence of rare variants in the HLA-G 3' UTR region in a cohort of 308 colorectal cancer patients in Italy.

**GSE122246:** NCBI GEO (Gene Expression Omnibus) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122246>)

Organism: Homo sapiens

Type: Expression profiling by high throughput sequencing

Platform: GPL17303 - 24 Samples

SeriesAccession: GSE122246 ID: 200122246

Last modification: May 3 2020

Contact name: Stefania Nobili

# Ref: RNA sequencing reveals PNN as a predictive biomarker of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. Mini E, Lapucci A, Perrone G, D'Aurizio R, Napoli C, Brugia M, Landini I, Tassi R, Picariello L, Simi L, Mancini I, Messerini L, Magi A, Pinzani P, Mazzei T, Tonelli F, Nobili S. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy. Int J Cancer. 145: 2580-2593 2019 doi 10.1002/ijc.32326

## PUBLICATIONS

Author of 85 peer reviewed original articles, reviews, editorials (<https://pubmed.ncbi.nlm.nih.gov/?term=nobili+s&sort=date&size=100>) (<https://www.scopus.com/authid/detail.uri?authorId=6602524021>) and 26 book chapters

## KEY BIBLIOMETRIC NUMBERS

**Total number of publications:** 85

**Journal Citation Reports (ISI) [2020] data:**

Cumulative Impact Factor: 537,208

Mean Impact Factor (n=78): 6,887

**Scopus data:**

Sum of the Times Cited: 3285

Documents found: 83

Average Citations per Item: 39.58

H-index: 27

Achievement of the threshold values for **BIO/14** for the qualification as **Full Professor** and **Member of the Committee for National Scientific Qualification (ASN)** according to the

Support System for the Evaluation of Scientific Production of CRUI – Evaluation based on parameters established by the decree ASN 2018 (DM 120, 7 June 2016, DM 589, 8 August 2018) ([https://s2.supporto](https://s2.supporto.crui.it) CRUI) - July 23, 2019

**Personal data** I authorize the processing of my personal data according to the Legislative Decree 30 June 2003, n. 196 “Codice in materia di protezione dei dati personali”.

July 28, 2021

Stefania Nobili